When: Reclaim of $91.10 (50 SMA) with positive MACD histogram

Then: Upgrade to Overweight at full benchmark+ sizing

Hold at or slightly below benchmark weight; wait for $82 entry confirmation rather than adding at $87.50; preserve capital to add on breakdowns rather than chase momentum into broken technicals.

• 50 SMA at $91.11 is a ceiling with sellers lining up, not a floor/magnet; reclaiming requires multi-week process with multiple confirming closes and MACD/RSI reversals
• RSI at 36.8 has not capitulated below 30 and MACD histogram is widening negative—bearish signal is fresh, not stale
• 25% ROIC and $3.46B FCF are real strengths but adjusted P/E reasoning is flawed; 21x forward remains premium vs historical 15-18x range even at 19x normalized
• 2.41% dividend yield is compressed versus 19-year high 10-year Treasury—yield spread basis shows limited margin of safety at current valuation
• Divestiture at 0.28x revenue multiple implies buyers paying essentially nothing; 0.3-0.4x range would mean giving away 17% of sales base with processes taking 6-18 months and no firm Q3 timeline
• Q3 earnings mid-October is major event risk; ATR compressed signals imminent volatility expansion with uncertain direction
• 80% FX exposure is headwind in strong dollar environment; 10-year Treasury at 19-year high mechanically compresses long-duration cash flow present value
• Entry at $87.50 versus waiting for $82 forgoes $5.50 or 6.3% per share of downside protection for two points of upside—unfavorable tradeoff in broken technical setup
• CL is down ~4% over past month, trading below 50-day, 200-day, and 10-day MAs simultaneously—absolute deterioration, not just relative outperformance
• Aggressive thesis requires three independent events (200 SMA holds, divestiture closes accretively, macro stays defensive) while conservative thesis simply requires holding and waiting for confirmation

→ vs aggressive: Risk-reward asymmetry claim is flawed: $5.50 downside ($87.50→$82) is not offset by $2.50 upside ($87.50→$90); $84.40-$84.50 zone is tested support with April/June precedents, not a vacuum—if it breaks, next support is 52-week low at $74.55 and March 2026 lows, representing ~$13 of risk, not $5.50

→ vs aggressive: Bearish narrative being 'stale' after one month is intellectually dishonest: RSI at 36.8 hasn't capitulated, MACD histogram widening negative is fresh deterioration, and persistent volume grind-lower shows sellers are patient, not exhausted; signals don't expire from calendar time, they expire when invalidated

→ vs aggressive: Adjusted P/E argument of 18-19x using one-line Q4 2025 charge normalization lacks rigor; even accepting 19x, still paying premium to historical 15-18x range, and 'reasonably priced for high quality' is opinion, not analysis—2.41% yield is full valuation with compressed spread vs 19-year high rates

→ vs aggressive: Divestiture being 'mechanically accretive' requires receiving a reasonable price; 0.28x revenue multiple implies giving away 17% of sales for essentially nothing, and 6-18 month timeline with mid-October Q3 update potentially being radio silence is not a near-term catalyst to underwrite

→ vs aggressive: Position sizing at 1.2-1.5x benchmark weight is overconfidence: name just closed below 200-day MA for first time in cycle, MACD widening negative, RSI in upper thirties, compressed ATR signaling imminent volatility expansion, October earnings event risk, 80% FX headwind, and 19-year high 10-year Treasury all compound risk unnecessarily

→ vs aggressive: Macro regime supporting defensives is a relative argument; CL down ~4% with price below all three moving averages simultaneously shows absolute deterioration—the aggressive analyst is saying 'it could have been worse,' which is a low bar, not a thesis

→ vs aggressive: Entry at $87.50 gives up $5.50 of downside protection for only $2.50 of upside—6.3% of position value for two points of upside capture is unfavorable insurance math in a name actively breaking down

HOLD at benchmark weight with a disciplined scaling plan: 50% on confirmed close above 200 SMA ($87.23) with RSI turning up, 50% scaled into $82-$84 zone if reached; tighten stop on confirmation tranche to $85.20; no new adds before Q3 earnings in mid-October

• Risk-reward reframed as ~1:1 on first target (Bollinger mid at $89.76), not the 2:1 the aggressive analyst claims by stacking targets
• First realistic upside target is $89.76, approximately $2.75 from current levels; 50 SMA at $91.11 is a tough ceiling but not required to make money
• Key support holding at $86.40 for 4 sessions after the Sept 11 breakdown at $86.80 on 5.77M shares
• Compressed ATR at 1.80 signals volatility expansion setup; direction unknown—coiled spring analogy applies
• MACD histogram widening negative is fresh deterioration, not stale; distribution has some exhaustion signs
• Valuation at 21x forward is FAIR, not cheap or expensive; CL has 25% ROIC, $3.46B trailing FCF, 2.41% dividend yield, 0.32 beta
• Dividend yield spread versus 19-year high 10-year Treasury is compressed—underweighted by both analysts
• Divestiture catalyst timeline is H2 2027 base case, not Q4 2026; proceeds redeployment visibility lacking
• 0.28x revenue divestiture multiple confirms assets were drag; removing them is accretive, not problematic
• Oil shock is a 2027 margin issue given CL's 12-18 month cost pass-through history
• Macro provides modest relative support (defensive) but absolute headwind (rates); forces roughly cancel
• Do not skip second tranche of scaling plan—confirmation is binary and failure risk requires the weakness tranche for protection
• Q3 earnings in mid-October will reset technical setup and provide guidance/divestiture update
• 200 SMA at $87.23 is key confirmation level; April consolidation floor provides additional downside bound
• 0.32 beta confirms defensive compounder characteristics, not high-risk momentum name

→ vs aggressive: Risk-reward math is padded by stacking two targets as if equally likely; actual stop-to-first-target is closer to 1:1, not 2:1

→ vs aggressive: Position sizing at 1.2-1.5x benchmark into broken 200 SMA, negative MACD, Q3 earnings risk, and 80% FX exposure is overconfidence, not conviction

→ vs aggressive: Treating this as momentum setup when it is a defensive compounder with 0.32 beta; path risk between now and earnings matters

→ vs aggressive: Q4 2026 divestiture re-rating timeline is unrealistic; H2 2027 is more appropriate base case

→ vs aggressive: Wants to buy at $87.50 on confirmation rather than following scaling plan—skips the protective second tranche that guards against confirmation failure

→ vs conservative: Implying institutional distribution is unlimited is wrong; distribution does exhaust—$86.40 support holding is meaningful price defense

→ vs conservative: Divestiture multiple concern conflates drag removal with negative impact; selling low-multiple assets removes drag and is accretive

→ vs conservative: Overweights technical breakdown while underweighting fundamental support at current levels

→ vs conservative: Suggests unlimited downside when 200 SMA ($87.23) and April consolidation floor provide bounded downside